The forecast for the import of insulin in dosage forms to Canada indicates a steady growth from 2024 to 2028, with values increasing from $402.75 million to $441.68 million. Compared to 2023, when the imports stood at approximately $393.20 million, this reflects consistent year-on-year growth, highlighting an expanding market demand for insulin driven by rising diabetes prevalence. From 2024 to 2028, the compound annual growth rate (CAGR) is approximately 2.3%, suggesting a stable market outlook.
Future trends to watch for include:
- Potential changes in healthcare policies affecting drug imports.
- Technological advancements in insulin production and alternatives.
- Evolving consumer preferences towards new diabetes treatments.
- Impacts of global economic conditions on import pricing and availability.
